Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2029

Sort by

Sort Order Select

Journal Articles

JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition

Vandana Chaturvedi, Nora Lakes, Minh Tran, Natalie Castillo, Michael B. Jordan

Blood (2021) 138 (12): 1034–1039.

https://doi.org/10.1182/blood.2020007930

Published: 2021

Journal Articles

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

Blood (2021) 137 (19): 2621–2633.

https://doi.org/10.1182/blood.2020007445

Published: 2021

Includes: Supplemental data

Journal Articles

Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism

Blood (2021) 137 (19): 2681–2693.

https://doi.org/10.1182/blood.2019004571

Published: 2021

Includes: Supplemental data

Journal Articles

TLR8 gain of function: a tall surprise

Bertrand Boisson, Jean-Laurent Casanova

Blood (2021) 137 (18): 2420–2422.

https://doi.org/10.1182/blood.2020010463

Published: 2021

Journal Articles

“Interferon” with MPN hematopoietic stem cells

Andrew Dunbar, Ross L. Levine

Blood (2021) 137 (16): 2129–2130.

https://doi.org/10.1182/blood.2021011273

Published: 2021

Journal Articles

JAK2 -V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality

Tata Nageswara Rao, Nils Hansen, Jan Stetka, Damien Luque Paz, Milena Kalmer, Julian Hilfiker, Max Endele, Nouraiz Ahmed, Lucia Kubovcakova, Margareta Rybarikova, Hui Hao-Shen, Florian Geier, Christian Beisel, Stefan Dirnhofer, Timm Schroeder, Tim H. Brümmendorf, Dominik Wolf, Steffen Koschmieder, Radek C. Skoda

Blood (2021) 137 (16): 2139–2151.

https://doi.org/10.1182/blood.2020005563

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting the p-D-C: easy as C-D-1-2-3?

Naveen Pemmaraju

Blood (2021) 137 (10): 1277–1278.

https://doi.org/10.1182/blood.2020008745

Published: 2021

Journal Articles

CD86-based analysis enables observation of bona fide hematopoietic responses

Masashi Kanayama, Yuta Izumi, Yasuharu Yamauchi, Shoko Kuroda, Takaei Shin, Shun Ishikawa, Taku Sato, Mihoko Kajita, Toshiaki Ohteki

Blood (2020) 136 (10): 1144–1154.

https://doi.org/10.1182/blood.2020004923

Published: 2020

Includes: Supplemental data

Journal Articles

Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder

Christopher Melani, Elaine S. Jaffe, Wyndham H. Wilson

Blood (2020) 135 (16): 1344–1352.

https://doi.org/10.1182/blood.2019000933

Published: 2020

Journal Articles

Erdheim-Chester disease

Julien Haroche, Fleur Cohen-Aubart, Zahir Amoura

Blood (2020) 135 (16): 1311–1318.

https://doi.org/10.1182/blood.2019002766

Published: 2020

Journal Articles

The role of type 1 interferons in coagulation induced by gram-negative bacteria

Xinyu Yang, Xiaoye Cheng, Yiting Tang, Xianhui Qiu, Zhongtai Wang, Guang Fu, Jianfeng Wu, Haixia Kang, Jing Wang, Haichao Wang, Fangping Chen, Xianzhong Xiao, Timothy R. Billiar, Ben Lu

Blood (2020) 135 (14): 1087–1100.

https://doi.org/10.1182/blood.2019002282

Published: 2020

Includes: Multimedia, Supplemental data

Journal Articles

Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis

Mounica Vallurupalli, Nancy Berliner

Blood (2019) 134 (21): 1783–1786.

https://doi.org/10.1182/blood.2019002289

Published: 2019

Journal Articles

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

Hong Mu-Mosley, MD PhD, Lauren B Ostermann, Muharrem Muftuoglu, MD, Wendy Schober, Nalini B Patel, Abishek Vaidya, MS, Challice L. Bonifant, MD PhD, Stephen Gottschalk, MD, Mireya Paulina Velasquez, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3917.

https://doi.org/10.1182/blood-2019-125928

Published: 2019

Journal Articles

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Susanne Bram Ednersson, MD, Mimmie Stern, MD, Henrik Fagman, Gunilla Enblad, Ulf-Henrik Mellqvist, MD PhD, Herman Nilsson-Ehle, MD PhD, Sverker Hasselblom, Per-Ola Andersson, MD PhD

Blood (2019) 134 (Supplement_1): 3967.

https://doi.org/10.1182/blood-2019-126387

Published: 2019

Journal Articles

Combined Thalidomide and Recombinant Human Interferon-α-1b and Interleukin-2 for Acute Myeloid Leukemia of Various Disease Status: A Multi-Center Prospective Study

Ruihua Mi, Lin Chen, MD, Xudong Wei, PhD, Xiaojiao WANG, Yongping Song, MD

Blood (2019) 134 (Supplement_1): 3865.

https://doi.org/10.1182/blood-2019-128431

Published: 2019

Journal Articles

DNA Methyltransferase Inhibitors Promote Homologous Recombination Deficiency through Induction of Immune Signaling, Sensitizing Acute Myeloid Leukemia Cells to PARP Inhibitors

Aksinija A Kogan, BS, MS, Lena J Mclaughlin, BS, Maria R. Baer, MD, Stephen Baylin, MD, Michael Topper, BS, Feyruz V. Rassool, BSc, PhD

Blood (2019) 134 (Supplement_1): 3763.

https://doi.org/10.1182/blood-2019-129535

Published: 2019

Journal Articles

Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia

Xiaohong Liu, Wenbing Duan, Jing Wang, MD, Jinsong Jia, Lizhong Gong, Shen-ye Lu, MD, Xiaosu Zhao, PhD, Ying-Jun Chang, Yue-Yun Lai, Hongxia Shi, Yu Wang, Chenhua Yan, Xiaojun Huang, MD, Hao Jiang

Blood (2019) 134 (Supplement_1): 3823.

https://doi.org/10.1182/blood-2019-128505

Published: 2019

Journal Articles

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Mariella D'Adda, MD, Mirko Farina, MD, Angela Passi, MD, Rosa Daffini, MD, Doriana Gramegna, MD, Elisa Cerqui, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Pagani, MD, Erika Borlenghi, MD, Diego Bertoli, PhD, Silvana Archetti, PhD, Mirella Marini, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 4146.

https://doi.org/10.1182/blood-2019-125313

Published: 2019

Journal Articles

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4032.

https://doi.org/10.1182/blood-2019-121723

Published: 2019

Journal Articles

Efficacy and Tolerance of Interferon-α in Hypereosinophilic Syndromes. a Retrospective Multicenter Study on 29 Patients

Pauline De Malglaive, MD, Matthieu Groh, MD, Guillaume Lefèvre, MD PhD, Chafika Morati Hafsaoui, MD, Magda Alexis, MD, Mathilde Hunault, MD PhD, Julien Seneschal, MD PhD, Hilaire Charlanne, MD, Claude Preudhomme, PharmD, PhD, Bernard Bonnotte, MD PhD, Jean Emmanuel Kahn, PhDMD

Blood (2019) 134 (Supplement_1): 2322.

https://doi.org/10.1182/blood-2019-131687

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism

TLR8 gain of function: a tall surprise

“Interferon” with MPN hematopoietic stem cells

JAK2 -V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality

Targeting the p-D-C: easy as C-D-1-2-3?

CD86-based analysis enables observation of bona fide hematopoietic responses

Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder

Erdheim-Chester disease

The role of type 1 interferons in coagulation induced by gram-negative bacteria

Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Combined Thalidomide and Recombinant Human Interferon-α-1b and Interleukin-2 for Acute Myeloid Leukemia of Various Disease Status: A Multi-Center Prospective Study

DNA Methyltransferase Inhibitors Promote Homologous Recombination Deficiency through Induction of Immune Signaling, Sensitizing Acute Myeloid Leukemia Cells to PARP Inhibitors

Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma

Efficacy and Tolerance of Interferon-α in Hypereosinophilic Syndromes. a Retrospective Multicenter Study on 29 Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only